Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model. (28th May 2017)

• Record Type: Journal Article
• Authors: Lee, Hwa Young; Hur, Jung; Kim, In Kyoung; Kang, Ji Young; Yoon, Hyoung Kyu; Lee, Sook Young; Kwon, Soon Suk; Kim, Young Kyoon; Rhee, Chin Kook
• Is Part Of: Experimental lung research. Volume 43:Number 4/5(2017)
• Page Start: 187
• Page End: 196
• Publication Date: 2017-05-28
• Subjects: chronic asthma -- fibroblast growth factor receptor (FGFR) -- nintedanib -- platelet-derived growth factor receptor (PDGFR) -- vascular endothelial growth factor receptor (VEGFR); Lungs -- Periodicals; Lungs -- Diseases -- Periodicals; Lung Diseases; Lung -- physiology; Respiratory System; 616.24
• DOI: 10.1080/01902148.2017.1339141
• Languages: English
• ISSNs: 0190-2148

Abstract

ABSTRACT: Introduction : Nintedanib is a multi-tyrosine kinase receptor inhibitor recently approved for treatment of idiopathic pulmonary fibrosis. Although angiogenesis is a key process involved in airway structural changes in patients with bronchial asthma, the effect of nintedanib targeting the angiokinase pathway on airway inflammation and remodeling has not been evaluated.Methods : We used a 3-month ovalbumin (OVA) challenge mouse model of airway remodeling. Nintedanib was orally administrated during the challenge period, and the effects were examined based on the percentage of airway inflammatory cells, airway hyper-reactivity (AHR), peribronchial goblet cell hyperplasia, total lung collagen and smooth muscle area. The expression of growth factor receptors was analyzed in mice lung tissues.Results : The OVA challenged group showed a significant increase in airway eosinophilic inflammation, elevated Th2 cytokines, AHR, and airway remodeling compared to those in the control group. The airway remodeling process, as evaluated by goblet cell hyperplasia, total lung collagen level, and airway smooth muscle area, was suppressed by nintedanib compared to that by OVA. Nintedanib effectively suppressed the phosphorylation of vascular endothelial growth factor/ platelet derived growth factor subunit2/fibroblast growth factor3 receptors in the mice lung.Conclusions : Nintedanib effectively ameliorated airway inflammation and remodeling in an OVA-induced chronic asthma model. These results suggest that nintedanib could be a new treatment agent targeting airway remodeling in patients with severe asthma.